EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Ravulizumab exposure in early pregnancy

Wolfgang Füreder, Sonja Granser, Andreas Repa, Alex Farr

Annals of Hematology · 13.10.2025 · 104 (11) · 6081-6084

DOI: 10.1007/s00277-025-06586-6 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Annals of Hematology, online erschienen am 13.10.2025. Verfasst von Wolfgang Füreder und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, A-1090, Austria. wol…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Hemoglobinuria, Paroxysmal, Pregnancy Complications, Hematologic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of Vienna.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Before complement inhibitors were available, pregnancy in women with paroxysmal nocturnal hemoglobinuria (PNH) was associated with considerable mortality, mainly due to thromboembolism. The complement-C5 inhibitor eculizumab has decreased this risk and improved pregnancy outcomes in women with PNH. Eculizumab has now largely been replaced by the longer acting ravulizumab in non-pregnant PNH patients. We report on ravulizumab exposure in early pregnancy in a 33 years-old PNH patient. She had become pregnant while on ravulizumab therapy and was switched to eculizumab in gestational week 11. Thus, exposure to ravulizumab occurred in a sensitive period of embryogenesis. Pregnancy was uneventful with a normal organ scan, followed by caesarean section. The male infant had an Apgar score of 9/9/10, without signs of perinatal morbidity. Birth weight was 3580 g, body length 53 cm, and head circumference 35.5 cm. The infant was fully breastfed and appeared well when being discharged home on the fourth day of life. Together, the use of ravulizumab during pregnancy in our patient was not harmful for the child. More data are needed to determine whether ravulizumab is indeed a safe treatment option for PNH in pregnancy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedHemoglobinuria, ParoxysmalPregnancy Complications, HematologicHumansPregnancyFemaleAdultMaleInfant, Newborn

Stichwörter der Autor:innen

EculizumabParoxysmal nocturnal hemoglobinuriaPregnancyRavulizumab

Substanzen

Antibodies, Monoclonal, Humanizedravulizumabeculizumab

Autor:innen und Institutionen

  • Department of Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, A-1090, Austria. wolfgang.fuereder@meduniwien.ac.at.
  • Department of Obstetrics and Gynecology, Division of Obstetrics and Feto-Maternal Medicine and Comprehensive Center for Pediatrics (CCP), Medical University of Vienna, Vienna, Austria.
  • Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.

Förderung

  • Medical University of Vienna

Zitieren

APA

Füreder, W., Granser, S., Repa, A., & Farr, A. (2025). Ravulizumab exposure in early pregnancy. Annals of Hematology, 104(11), 6081-6084. https://doi.org/10.1007/s00277-025-06586-6

Vancouver

Füreder W, Granser S, Repa A, Farr A. Ravulizumab exposure in early pregnancy. Annals of Hematology. 2025;104(11):6081-6084. doi:10.1007/s00277-025-06586-6

BibTeX
@article{Freder2025,
  author = {Füreder, Wolfgang and Granser, Sonja and Repa, Andreas and Farr, Alex},
  title = {Ravulizumab exposure in early pregnancy},
  journal = {Annals of Hematology},
  year = {2025},
  volume = {104},
  number = {11},
  pages = {6081--6084},
  doi = {10.1007/s00277-025-06586-6}
}
Kostenlos starten →